Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.4.1.41 - polypeptide N-acetylgalactosaminyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines.
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas.
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
N-acetylgalactosaminyltransferase: a potential target for colorectal adenocarcinoma.
Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells.
The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma.
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Adenocarcinoma of Lung
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.
Adenocarcinoma, Mucinous
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Adenoma
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome.
Anemia, Sickle Cell
Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).
Atherosclerosis
Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis.
Identification of CAD candidate genes in GWAS loci and their expression in vascular cells.
Brain Neoplasms
Glycosyltransferase activities in human meningiomas. Preliminary results.
Breast Neoplasms
An anti-human ppGalNAcT-2 monoclonal antibody.
Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells.
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion.
Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
Estrogen Regulates Vesicle Trafficking Gene Expression in EFF-3, EFM-19 and MCF-7 Breast Cancer Cells.
GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.
GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells.
GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment.
GALNT3 Maintains the Epithelial State in Trophoblast Stem Cells.
Glycosyltransferases as Markers for Early Tumorigenesis.
LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity.
Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression.
Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown.
N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
Osterix Decreases the Chemosensitivity of Breast Cancer Cells by Upregulating GALNT14.
Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene.
ppGalNAc-T4-catalyzed O-Glycosylation of TGF-? type ? receptor regulates breast cancer cells metastasis potential.
Prognostic utility of glycosyltransferase expression in breast cancer.
Reduced expression of ppGalNAc-T4 promotes proliferation of human breast cancer cells.
RNA interference-mediated silencing of ppGalNAc-T1 and ppGalNAc-T2 inhibits invasion and increases chemosensitivity potentially by reducing terminal ?2,3 sialylation and MMP14 expression in triple?negative breast cancer cells.
The Role for GALNT14 in the lung metastasis of breast cancer.
The role of ppGalNAc-T family in breast cancer development and progression.
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.
Calcinosis
A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
A Cross-Sectional Cohort Study of the Effects of FGF23 Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis.
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
A Mouse with an N-Ethyl-N-Nitrosourea (ENU) Induced Trp589Arg Galnt3 Mutation Represents a Model for Hyperphosphataemic Familial Tumoural Calcinosis.
A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
A novel homozygous variant in exon 10 of the GALNT3 gene causing hyperphosphatemic familial tumoral calcinosis in a family from North India.
Ablation of the Galnt3 gene leads to low circulating intact Fgf23 concentrations and hyperphosphatemia despite increased Fgf23 expression.
Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.
Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study.
Bone Involvement in Hyperphosphatemic Familial Tumoral Calcinosis: A New Phenotypic Presentation.
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.
Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.
GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis.
GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Giantin-knockout models reveal a feedback loop between Golgi function and glycosyltransferase expression.
Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.
Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey
Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti-Interleukin-1 Treatments.
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and ?Klotho).
Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.
Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
Novel Regulators of Phosphate Homeostasis and Bone Metabolism.
Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.
Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Reply to ultrastructural study of the clinically uninvolved skin in familial tumoral calcinosis caused by mutations in GALNT3.
Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.
Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Two novel GALNT3 mutations in familial tumoral calcinosis.
Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis.
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]
[Tumoral calcinosis]
Carcinogenesis
Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis.
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.
GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.
GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of ?2M.
GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition.
Molecular profiling of chordoma.
Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.
Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome.
Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling.
The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation.
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma
An anti-human ppGalNAcT-2 monoclonal antibody.
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.
Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.
GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Molecular cloning of the human beta1,4 N-acetylgalactosaminyltransferase responsible for the biosynthesis of the Sd(a) histo-blood group antigen: the sequence predicts a very long cytoplasmic domain.
Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
ppGalNAc T1 as a potential novel marker for human bladder cancer.
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma.
Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype.
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells.
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Carcinoma, Ductal
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma, Embryonal
Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation.
CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C.
Carcinoma, Endometrioid
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Carcinoma, Hepatocellular
A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Exosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
GALNT14 genotype, ?-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons.
Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Carcinoma, Intraductal, Noninfiltrating
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma, Medullary
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Carcinoma, Non-Small-Cell Lung
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
miR-365b regulates the development of non-small cell lung cancer via GALNT4.
Carcinoma, Ovarian Epithelial
Altered expression of different GalNAc?transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
Carcinoma, Papillary
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Carcinoma, Renal Cell
Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Carcinoma, Signet Ring Cell
Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype.
Carcinoma, Squamous Cell
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
Cholangiocarcinoma
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling.
Chordoma
Molecular profiling of chordoma.
Colonic Neoplasms
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
MiR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: involvement of GALNT4.
miR?4262 inhibits colon cancer cell proliferation via targeting of GALNT4.
Polypeptide-GalNAc-T6 expression predicts better overall survival in patients with colon cancer.
Colorectal Neoplasms
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer.
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas.
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
GALNT12 is not a major contributor of familial colorectal cancer type X.
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Inherited deleterious variants in GALNT12 are associated with CRC susceptibility.
Intracellular inhibition of blood group A glycosyltransferase.
LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1.
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3.
The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation.
The structure of the colorectal cancer-associated enzyme GalNAc-T12 reveals how nonconserved residues dictate its function.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clinical Utility Gene Card For: GALNT3 defective congenital disorder of glycosylation.
Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Coronary Artery Disease
Genetic polymorphisms in platelet-related proteins and coronary artery disease: investigation of candidate genes, including N-acetylgalactosaminyltransferase 4 (GALNT4) and sulphotransferase 1A1/2 (SULT1A1/2).
Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.
Variant in GALNT3 Gene Linked with Reduced Coronary Artery Disease Risk in Chinese Population.
Coronary Disease
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
Cysts
Cyst wall synthase: N-acetylgalactosaminyltransferase activity is induced to form the novel N-acetylgalactosamine polysaccharide in the Giardia cyst wall.
Making Home Sweet and Sturdy: Toxoplasma gondii ppGalNAc-Ts Glycosylate in Hierarchical Order and Confer Cyst Wall Rigidity.
De Lange Syndrome
Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation.
Diabetes Mellitus
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Diabetes Mellitus, Type 1
IDDM7 links to insulin-dependent diabetes mellitus in Danish multiplex families but linkage is not explained by novel polymorphisms in the candidate gene GALNT3. The Danish Study Group of Diabetes in Childhood and The Danish IDDM Epidemiology and Genetics Group.
Diabetes Mellitus, Type 2
GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Diabetes, Gestational
Maternal GALNT2 Variations Affect Blood Pressure, Atherogenic Index, and Fetal Growth, Depending on BMI in Gestational Diabetes Mellitus.
Dry Eye Syndromes
Expression in human ocular surface tissues of the GalNAc-transferases that initiate mucin-type O-glycosylation.
Dwarfism
Overexpression of Galnt3 in chondrocytes resulted in dwarfism due to the increase of mucin-type O-glycans and reduction of glycosaminoglycans.
Dyslipidemias
GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?
Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells.
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
Endometrial Hyperplasia
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Endometrial Neoplasms
Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
GalNAc-T6 in the relationship with invasion ability of endometrial carcinomas and prognostic significance.
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Endometriosis
Correlation of polypeptide N-acetylgalactosamine transferases-3 and -6 to different stages of endometriosis.
Esophageal Squamous Cell Carcinoma
GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.
Eye Diseases
Autosomal recessive non-syndromic keratoconus: Homozygous frameshift variant in the candidate novel gene GALNT14.
Familial Hypophosphatemic Rickets
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
Gastrointestinal Neoplasms
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.
Genetic Diseases, Inborn
A sequence-coupled vector-projection model for predicting the specificity of GalNAc-transferase.
Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey
Glioblastoma
Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen.
Effects of IGFBP-3 and GalNAc-T14 on proliferation and cell cycle of glioblastoma cells and its mechanism.
High expression of GALNT7 promotes invasion and proliferation of glioma cells.
Glioma
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.
High expression of GALNT7 promotes invasion and proliferation of glioma cells.
Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Glomerulonephritis, IGA
Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy.
Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy.
Heart Defects, Congenital
Galnt1 is required for normal heart valve development and cardiac function.
Heart Diseases
Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.
Hemorrhagic Fever, Ebola
Site-specific glycosylation of Ebola virus glycoprotein by human polypeptide GalNAc-transferase 1 induces cell adhesion defects.
Herpes Simplex
N-acetylgalactosaminyltransferase activity involved in O-glycosylation of herpes simplex virus type 1 glycoproteins.
Hyperglycemia
GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.
Hyperostosis
Giantin-knockout models reveal a feedback loop between Golgi function and glycosyltransferase expression.
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Phosphatonins: physiological role and pathological changes.
Hyperphosphatemia
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ablation of the Galnt3 gene leads to low circulating intact Fgf23 concentrations and hyperphosphatemia despite increased Fgf23 expression.
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification.
GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Phosphatonins: physiological role and pathological changes.
Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]
Hypertension
Gene environment interaction of GALNT2 and APOE gene with hypertension in the Chinese Han Population.
Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.
Hypophosphatemia
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Immune System Diseases
Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.
Infections
Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.
The C-type lectin receptor MGL senses N-acetylgalactosamine on the unique Staphylococcus aureus ST395 wall teichoic acid.
Infertility
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Infertility, Male
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Influenza, Human
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.
Insulin Resistance
GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.
Ischemic Stroke
Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke.
Keratoconus
Autosomal recessive non-syndromic keratoconus: Homozygous frameshift variant in the candidate novel gene GALNT14.
Leukemia
Expressions of polypeptide: N-acetylgalactosaminyltransferase in leukemia cell lines during 1,25-dihydroxyvitamin D3 induced differentiation.
Leukemia, Lymphocytic, Chronic, B-Cell
GALNT11 as a new molecular marker in chronic lymphocytic leukemia.
Leukopenia
GALNT14 genotype, ?-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.
Liver Diseases
Glycosyltransferases in human blood. II. Study of serum galactosyltransferase and N-acetylgalactosaminyltransferase in patients with liver diseases.
Liver Neoplasms
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.
Lung Neoplasms
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Correction to: Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis.
miR-365b regulates the development of non-small cell lung cancer via GALNT4.
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
Lupus Nephritis
A longitudinal and transancestral analysis of DNA methylation patterns and disease activity in lupus patients.
Lymphatic Metastasis
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Lymphoma
Purification and characterization of UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase from bovine colostrum and murine lymphoma BW5147 cells.
[Demonstration of N-acetylgalactosaminyltransferase activity in the murine lymphoma YC8]
Melanoma
Analysis of melanoma cells stably transfected with beta 1,4GalNAc transferase (GM2/GD2 synthase) cDNA: relative glycosyltransferase levels play a dominant role in determining ganglioside expression.
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.
Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
Meningioma
Glycosyltransferase activities in human meningiomas. Preliminary results.
Mucopolysaccharidoses
Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
Mucopolysaccharidosis III
Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.
Muscular Dystrophies
Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism.
Myopia
Lack of association with high myopia and the MYP2 locus in the Japanese population by high resolution microsatellite analysis on chromosome 18.
Neoplasm Metastasis
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment.
GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity.
LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1.
Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
The Role for GALNT14 in the lung metastasis of breast cancer.
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.
Neoplasms
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer.
Altered expression of different GalNAc?transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy.
Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22.
Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis.
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer.
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Dual-signal electrochemical sensor for detection of cancer cells by the split primer ligation-triggered catalyzed hairpin assembly.
Early GalNAc O-Glycosylation: Pushing the Tumor Boundaries.
Efficient monitoring of enzymatic conjugation reaction by surface-enhanced laser desorption/ionization time of flight mass spectrometry for process optimization.
Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates.
Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.
Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population.
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines.
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.
Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas.
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
GalNAc-T6 in the relationship with invasion ability of endometrial carcinomas and prognostic significance.
GALNT12 is not a major contributor of familial colorectal cancer type X.
GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
GALNT6 suppresses progression of colorectal cancer.
GALNT9 gene expression is a prognostic marker in neuroblastoma patients.
Ganglioside biosynthetic gene expression in experimental mouse brain tumors.
Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
Glyco-genes change expression in cancer through aberrant methylation.
Identification of GALNT14 as a novel neuroblastoma predisposition gene.
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis.
Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase.
Inherited deleterious variants in GALNT12 are associated with CRC susceptibility.
Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.
Isolation of a Golgi-apparatus-enriched fraction from leukaemic cells.
Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4.
Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
N-acetylgalactosaminyltransferases in cancer.
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.
Photo-modulation of zinc phthalocyanine-treated breast cancer cell line ZR-75-1 inhibited the normal tumor activity in vitro.
Poly (A)? transcriptome assessment of ERBB2-induced alterations in breast cell lines.
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer.
Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.
Polypeptide-GalNAc-T6 expression predicts better overall survival in patients with colon cancer.
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma.
Reduced expression of ppGalNAc-T4 promotes proliferation of human breast cancer cells.
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Relationship of gangliosides to the structure and function of thyrotropin receptors: their absence on plasma membranes of a thyroid tumor defective in thyrotropin receptor activity.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer.
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
The transcriptional profiling of glycogenes associated with hepatocellular carcinoma metastasis.
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
Treatment of cancer stem cells from human colon adenocarcinoma cell line HT-29 with resveratrol and sulindac induced mesenchymal-endothelial transition rate.
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
[Prokaryotic expression and antibody preparation of human GALNT3-sol protein].
Neuroblastoma
Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen.
GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
GALNT9 gene expression is a prognostic marker in neuroblastoma patients.
Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Identification of GALNT14 as a novel neuroblastoma predisposition gene.
Obesity
GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling.
Oligospermia
Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia.
Osteomyelitis
GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis.
Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Osteoporosis
Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study.
Association of genetic polymorphisms of GALNT3 and VDR with osteoporosis in postmenopausal women.
Research on correlation between GALNT3 gene and osteoporosis.
Osteosarcoma
High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.
Molecular mechanisms of cadmium-induced FGF23 upregulation in osteoblast-like cells.
Ovarian Neoplasms
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies.
BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
Pancreatic Neoplasms
Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.
Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival.
The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer.
Polycystic Ovary Syndrome
GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.
polypeptide n-acetylgalactosaminyltransferase deficiency
Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.
Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia.
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.
Prostatic Neoplasms
Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4.
Pulmonary Valve Stenosis
Galnt1 is required for normal heart valve development and cardiac function.
Rickets, Hypophosphatemic
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Molecular cloning of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T8, and analysis as a candidate autosomal dominant hypophosphatemic rickets (ADHR) gene.
Sarcoma
Glycolipid N-acetylgalactosaminyltransferase activities in normal and Kirsten murine sarcoma virus transformed BALB/c 3T3 cells.
Solitary Pulmonary Nodule
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
Squamous Cell Carcinoma of Head and Neck
An anti-human ppGalNAcT-2 monoclonal antibody.
Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Stomach Neoplasms
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs.
Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer.
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase.
Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer.
Polypeptide:N-acetylgalactosaminyltransferase activities towards the mucin MUC5AC peptide motif using microsomal preparations of normal and tumoral digestive mucosa.
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Stroke
Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke.
Teratoma
Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation.
Thyroid Neoplasms
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Urinary Bladder Neoplasms
GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
ppGalNAc T1 as a potential novel marker for human bladder cancer.
Uterine Cervical Neoplasms
MicroRNA-214 Suppresses The Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.
Virus Diseases
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Generation of Human Bronchial Epithelial Cell Lines Expressing Inactive Mutants of GALNT3.
Williams Syndrome
A Putative Polypeptide N-Acetylgalactosaminyltransferase/Williams-Beuren Syndrome Chromosome Region 17 (WBSCR17) Regulates Lamellipodium Formation and Macropinocytosis.